Table 7 Main AEs’ rates (for grades 1–5) in present series compared to literature data on BZB and TH in oncology (or other) settings
From: Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia
Present study % | ||
|---|---|---|
Bevacizumab | ||
Hypertension | 7.2 | 5–19 |
Bleeding | 2.8 | 1.7–6.7 |
Proteinuria | 2.8 | 0.7–7.4 |
Arterial thromboembolism | 1.4 | 0.7–4.4 |
Peripheral neuropathy | Not described | 6.3 |
Thalidomide | ||
Somnolence/drowsiness | 16 | 2–23 |
Peripheral neuropathy | 17.9 | 1–44 |
Thromboembolic event | 2.9 | 1–6 |
Cardiac failure | 1.4 | 1–8 |
Bleeding | 1.4 | Not described |